Novo’s Obesity Franchise On Track For YE22 But Diabetes Pipeline Steals Show During Q3
As Lilly’s Rival Beats Expectations
Updates regarding Novo Nordisk’s obesity product Wegovy dominated the Danish firm’s Q3 results call, but observers were also keen to hear of diabetes R&D milestones as Eli Lilly’s competitor Mounjaro entered the market with a bang.
